Get started
Author

Maud Brandely

Observed names: M. Brandely, Maud Brandely-Talbot
Institution: Transgene (France)
Observed institutions: Universidade Federal da Bahia, Transgene (France), Inserm, Institut Pasteur, Cornell University, Pierre Fabre (France), Fondation ARC pour la Recherche sur le Cancer, Institut Paoli-Calmettes, Institut Curie
ORCID: 0009-0005-6058-1681
Observed ORCID: 0009-0005-6058-1681
OpenAlex ID: A5110158698
Treatment of Visceral Leishmaniasis with Pentavalent Antimony and Interferon Gamma
1990 · Roberto Badaro, Ernesto Falcoff, et al. · New England Journal of Medicine · 308
PDF
Intrapleural Recombinant IL-2 in Passive Immunotherapy for Malignant Pleural Effusion
1993 · Philippe Astoul, Jean-Regis Viallat, et al. · CHEST Journal · 94
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial
2019 · Fabien Zoulim, Claire Fournier, et al. · Human Vaccines & Immunotherapeutics · 91
PDF
A Phase II Study of Interleukin-2 in 49 Patients with Relapsed or Refractory Acute Leukemia
1998 · Dominique Maraninchi, Norbert Vey, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 54
Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma
1993 · Pierre Wolkenstein, Olivier Chosidow, et al. · Journal of the American Academy of Dermatology · 49
The Use of a Sequential High Dose Recombinant Interleukin 2 Regimen After Autologous Bone Marrow Transplantation Does Not Improve the Disease Free Survival of Patients with Acute Leukemia Transplanted in First Complete Remission
1997 · Didier Blaise, Michel Attal, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 47
Recombinant Human γ–Interferon in Patients With Chronic Active Hepatitis B: Pharmacokinetics, Tolerance and Biological Effects
1990 · Patrick Marcellin, Marie-Anne Loriot, et al. · Hepatology · 43
PDF
Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers
2023 · Edith Borcoman, Ana Lalanne, et al. · European Journal of Cancer · 23
A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
2025 · Emma J. West, Alain Sadoun, et al. · Clinical Cancer Research · 21
Increased expression of perforin and granzyme B genes in patients with metastatic melanoma treated with recombinant interleukin-2
1994 · Marie-B�n�dicte Leger-Ravet, Claire Mathiot, et al. · Cancer Immunology Immunotherapy · 18
Cell Surface Expression of ICAM-1 (CD54) and LFA-3 (CD58), Two Adhesion Molecules, Is Up-Regulated on Bone Marrow Leukemic Blasts After In Vivo Administration of High-Dose Recombinant Interleukin-2
1991 · Daniel Olive, Marc Lopez, et al. · Journal of Immunotherapy · 18
Interferon-γ (IFN-γ) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity — IFN-γ-induced suppressive activity
1989 · Michel Toledano, Claire Mathiot, et al. · Cancer Immunology Immunotherapy · 18
A Pilot Study of Autologous Bone Marrow Transplantation Followed by Recombinant Interleukin-2 in Malignant Lymphomas
1996 · Norbert Vey, Didier Blaise, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 15
Effects of Suramin on the immune responses to sheep red blood cells in mice
1985 · Maud Brandely, Philippe Lagrange, et al. · Cellular Immunology · 14
A phase I trial with recombinant interferon γ (Roussel UCLAF) in advanced cancer patients
1990 · François Boue, Zulay Pastran, et al. · Cancer Immunology Immunotherapy · 12
Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma.
2023 · Christian H.H. Ottensmeier, Jean-Pierre Delord, et al. · Journal of Clinical Oncology · 11
Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC).
2022 · Jean-Pierre Delord, Matthew Stephen Block, et al. · Journal of Clinical Oncology · 9
Treatment of Chronic Myelogenous Leukemia with Interleukin-2: A Phase II Study in 21 Patients
1999 · Norbert Vey, Didier Blaise, et al. · Journal of Immunotherapy · 9
Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer
2008 · Mario Campone, Maria Blasinska-Morawiec, et al. · Cancer Chemotherapy and Pharmacology · 8
Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: Results of a pharmacokinetic study
2009 · Jos J. Kitzen, Christian Puozzo, et al. · European Journal of Cancer · 7
Effects of Suramin on the immune responses to sheep red blood cells in mice
1985 · Iris Motta, Maud Brandely, et al. · Cellular Immunology · 5
Vinflunine Oral Pharmacokinetics and Absolute Bioavailability of Soft and Hard Gelatin Capsules
2012 · Jean-Pierre Delord, Jaafar Bennouna, et al. · Clinical Pharmacokinetics · 4
Interleukin-2-induced increase of a monoclonal b-cell lymphocytosis. A novel In vivo interleukin-2 effect?
1992 · Pierre Tiberghien, Evelyne Racadot, et al. · Cancer · 3
A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial
2026 · Christian Ottensmeier, Jean-Pierre Delord, et al. · Nature Communications · 1
PDF
650 Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)
2024 · Christophe Le Tourneau, Jean-Pierre Delord, et al. · Regular and Young Investigator Award Abstracts · 1
Works count: 44
Citation count: 886
H-index: 14
I10-index: 16
Year
Topic
Type